BAYER TO PRESENT XARELTO DATA FROM EINSTEIN TRIALS IN DEC. (ENG)
(The following press release from Bayer was received by e-mail. It was not confirmed by the sender.)
Not intended for U.S. and UK Media: 54th American Society of Hematology (ASH) Annual Meeting and Exposition 2012: New data on Bayer’s Xarelto® (Rivaroxaban) as a Single-Drug Solution for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Pooled data from EINSTEIN trials show oral rivaroxaban has an improved benefit-risk profile and lower rates of major bleeding compared with standard therapy / New data also show reduced hospital stay and improved patient-reported satisfaction with rivaroxaban for patients with acute symptomatic PE
Berlin, Germany, November 30, 2012 - Bayer HealthCare announced today that new data from the clinical development programme for its oral anticoagulant Xarelto® (rivaroxaban) will be presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, GA, USA, December 8-11, 2012. These data underscore the benefits of rivaroxaban for patients at risk of dangerous blood clots across multiple venous thromboembolic conditions.
Notable data analyses to be presented at ASH 2012 include:
• Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism:
A Pooled Analysis of the EINSTEIN DVT and EINSTEIN PE Studies https://ash.confex.com/ash/2012/webprogram/Paper51556.html o Oral Presentation: Session 332. Antithrombotic Therapy I; 12:15 o Saturday, December 8, 2012; 12:00 - 13:30; Georgia World Congress Center, B405-B407
• Patient-Reported Treatment Satisfaction with Oral Rivaroxaban versus Standard Therapy in the Treatment of Acute Symptomatic Pulmonary Embolism https://ash.confex.com/ash/2012/webprogram/Paper51526.html o Poster Session: Session 332. Antithrombotic Therapy: Poster I o Saturday, December 8, 2012; 17:30 - 19:30; Georgia World Congress Center, Hall B1-B2
• Reduction in Initial Length of Stay with Rivaroxaban Single-Drug Regimen versus LMWH-VKA Standard of Care: Findings from the EINSTEIN Trial Program https://ash.confex.com/ash/2012/webprogram/Paper51519.html o Poster Session: Session 332. Antithrombotic Therapy: Poster III o Monday, December 10, 2012; 18:00 - 20:00; Georgia World Congress Center, Hall B1-B2
The pivotal EINSTEIN Clinical Trial Programme comprises three Phase III studies evaluating rivaroxaban alone versus the dual-drug regimen of low molecular weight heparin (LMWH) and vitamin K antagonist (VKA) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE.
Xarelto has been approved as a single-drug solution for the treatment of DVT and PE as well as the prevention of recurrent DVT and PE in adults in a number of countries worldwide including Europe and the U.S.
About Xarelto® (Rivaroxaban) Rivaroxaban is the most broadly indicated new oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto is approved for use in the following venous arterial thromboembolic (VAT) indications:
• The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors • The treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) in adults • The treatment of PE and prevention of recurrent DVT and PE in adults • The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery
Whilst licences may differ from country to country, across all indications Xarelto is approved in more than 120 countries.
Rivaroxaban was discovered by Bayer HealthCare, and is being jointly developed with Janssen Research & Development, LLC. Xarelto is marketed outside the U.S. by Bayer HealthCare and in the U.S. by Janssen Pharmaceuticals, Inc. (a Johnson & Johnson Company).
Anticoagulant medicines are potent therapies used to prevent or treat serious illnesses and potentially life threatening conditions. Before initiating therapy with anticoagulant medicines, physicians should carefully assess the benefit and risk for the individual patient.
Responsible use of Xarelto is a high priority for Bayer, and the company has developed a Prescribers Guide for physicians and a Xarelto Patient Card for patients to support best practice.
To learn more, please visit: https://prescribe.xarelto.com To learn more about thrombosis, please visit http://www.thrombosisadviser.com To learn more about Xarelto, please visit http://www.xarelto.com
About Bayer HealthCare The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. More information at http://www.healthcare.bayer.com.
Our online press service is just a click away: http://press.healthcare.bayer.com
Find more information at http://www.bayerpharma.com.
Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at http://www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Contact: Bayer Pharma AG Astrid Kranz, Tel. +49 30 468-12057 E-Mail: mailto:firstname.lastname@example.org
This press release is available here: http://www.baynews.bayer.de/baynews/baynews.nsf/id/2012-0545-e
Yours BayNews Editorial Team
Bayer AG Communications Building W11 51368 Leverkusen, Germany
Further news releases you can find here: http://www.press.bayer.com